This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why Repros Therapeutics (RPRX) Stock Is Surging Today

NEW YORK (TheStreet) -- Repros Therapeutics (RPRX) surged in morning trading Thursday after the company announced its testosterone treatment showed superiority to an FDA-approved topical gel.

The company reported top-line results for the first of two identical studies that compared its treatment, Androxal, with the leading FDA-approved Androgel. Androxal showed superiority in multiple assessments, specifically the two co-primary endpoints of percent change from baseline in average sperm concentration and percent of subjects considered to be responders.

The study defines a responder as "an individual achieving a 24-hour average testosterone in the normal range with associated average sperm concentration >= 10 million/mL," according to the press release.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Androxal also showed superiority in secondary endpoints, including change in the key pituitary signaling hormones LH and FSH.

The stock was up 10.21% to $20.07 at 9:59 a.m. More than 2.1 million shares had changed hands, compared to the average volume of 258,220.

RPRX Chart RPRX data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.


Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
RPRX $7.32 -0.48%
AAPL $111.69 0.08%
FB $94.23 -0.03%
GOOG $650.64 0.61%
TSLA $219.20 1.70%


Chart of I:DJI
DOW 17,102.30 -29.56 -0.17%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,833.1270 -5.5160 -0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs